EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Daiichi Sankyo Company Limited (DSKYF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Daiichi Sankyo Company Limited $8.25, price $17.60, upside -53.1%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US

DS Daiichi Sankyo Company Limited logo Broad data Sep 28, 2026

Daiichi Sankyo Company Limited

DSKYF · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $8.25 · Strongly overvalued (−53.1%)
!Quality 51/100
!Expensive Growth (revenue 5y +17.3 %/yr)
✓Solidly profitable · 12.2% net margin (TTM)
!Low debt · negative free cash flow
!4.2% dividend yield · Watch coverage
!Mixed vs. peers (8/14)
!Moderate moat 54/100
Watch Daiichi Sankyo Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$41.87 $14.76 Fair Value $8.25 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range $14.76 – $41.87 · fair‑value band $5.93 – $10.91 · the $17.60 price screens above the $8.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.

Follow Daiichi Sankyo Company in your weekly email

Every Wednesday you see whether Daiichi Sankyo Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.

Show more

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. It has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research; Daiichi Sankyo Company, Limited has a strategic collaboration with Leica Biosystems and AstraZeneca to develop an immunohi

Stock analysis

Daiichi Sankyo Company Limited (DSKYF) currently trades at $17.60, while our model-based Fair Value estimate is $8.25, 53.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $17.63 per share, and 3 of the 17 models we run sit above the $17.60 price.

Bear case: the Asset-Based group reads lowest at $3.91, and 14 of the 17 models stay below the price. Evidence for this calculation is high.

Scenario range: $5.93 (bear) to $10.91 (bull), the price of $17.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Daiichi Sankyo Company Limited reported revenue of ¥2.1T in FY2026 versus ¥1.0T in FY2022, a compound +19.6%/yr. Reported net income was ¥262B in FY2026, compounding +40.6%/yr from FY2022.

Key figures

Market cap $32.6B · P/E ratio 20.0 · P/S ratio 2.45 · EPS (TTM) $0.8800 · Dividend yield 4.2% · Net margin 12.2% · Return on equity 15.8% · Return on assets (EBIT) 5.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (medium confidence).

What moves the price

The share trades about 37% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −53%, DSKYF screens richer than that median.

Fair Value models

Bear $5.93 Fair Value $8.25 Bull $10.91
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings $9.81 $14.58 $21.84 76
Residual Income $6.00 $7.62 $11.17 75
EPV $7.45 $8.49 $9.40 74
All 17 models by family
DCF Models
Owner Earnings $9.81 $14.58 $21.84 76
Earnings-Based
Graham-Dodd $6.19 $19.18 $25.49 65
Lynch FV $4.16 $5.94 $7.72 61
PEG = 1.0 $4.16 $5.94 $7.72 57
EPV $7.45 $8.49 $9.40 74
Dividend Discount
Gordon GGM $4.13 $8.59 $13.63 66
DDM Multi-Stage $4.13 $6.82 $9.02 66
Multiples
P/E Multiple $15.02 $20.03 $25.04 63
P/S Multiple $11.61 $15.48 $19.35 58
P/B Multiple $11.61 $15.48 $19.35 55
EV/EBIT $10.49 $13.57 $16.66 66
EV/EBITDA $11.70 $15.19 $18.69 67
EV/Revenue $7.83 $10.67 $13.50 54
Asset-Based
NCAV (Graham) $2.92 $3.91 $5.83 54
Economic Profit
Residual Income $6.00 $7.62 $11.17 75
ROIC Compounder $7.79 $9.59 $11.78 72
Growth Earnings
Growth-Adj P/E $12.34 $17.63 $22.92 67

Open the full fair value analysis →

Notify me when DSKYF reaches fair value

Put DSKYF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 49 · Market factors (momentum, volatility) 36

Profitability 52
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 56
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2021 (pandemic). Over 10 years: +8.0% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.2%
Dividend (yield on the price)4.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.29.3% vs 13.5%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 10%
Start year 2021 (pandemic)

DSKYF screens overvalued: fair value 53% below the price. Compare with Eli Lilly and Company →

Compare Daiichi Sankyo Company Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside −53.8% · Bottom 25%
Profitability
Return on equity (TTM) 15.8% · Above median
Return on assets 3.8% · Below median
Net margin (TTM) 12.2% · Above median
Operating margin (TTM) −0.8% · Bottom 25%
Growth and dividend
Revenue growth 13.7% · Above median
Dividend yield (TTM) 4.2% · Top 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 20.0× · Cheaper than median
P/B 3.07× · Pricier than median
P/S (TTM) 2.42× · Cheaper than median
EV/EBITDA 15.6× · Pricier than median
PEG 1.75× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)69 · sector 33
PAST (return on equity)63 · sector 41
HEALTH (low debt)97 · sector 92
DIVIDEND (yield)85 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,157 $749.08 −35%
Johnson & Johnson, JNJ $264.74 $168.85 −36%
AbbVie Inc ABBV $261.59 $259.62 −1%
Roche Holding RO CHF 375.20 CHF 326.56 −13%
Merck & Co MRK $143.81 $129.26 −10%
Novartis AG NOVN CHF 118.06 CHF 121.90 +3%
Amgen Inc AMGN $421.51 $463.66 +10%
Gilead Sciences, Inc GILD $149.05 $198.77 +33%
Pfizer Inc PFE $28.12 $24.87 −12%
Bristol-Myers Squibb Company BMY $62.40 $75.96 +22%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Daiichi Sankyo Company Limited · Fair Value
$8.25 −53%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Daiichi Sankyo Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/DSKYF

Frequently asked questions

Is Daiichi Sankyo Company Limited (DSKYF) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of $8.25 versus a price of $17.60, about −53% upside (overvalued).
What is the fair value of DSKYF?
Our model-based fair value for Daiichi Sankyo Company Limited is $8.25 (as of Sep 28, 2026), built from audited fundamentals. The current price: $17.60.
What is the quality score of DSKYF?
Daiichi Sankyo Company Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daiichi Sankyo Company Limited (DSKYF)?
Our model-based price target is the fair value of $8.25 (as of Sep 28, 2026) from 17 valuation models. Cautious scenario $5.93, optimistic scenario $10.91. It is a calculation from audited fundamentals, not an analyst target.
What is the Daiichi Sankyo Company Limited stock forecast for 2026?
Our models put fair value at $8.25, about −53% upside versus a price of $17.60 (overvalued). Cautious scenario $5.93, optimistic scenario $10.91. The calculation is refreshed regularly with new filings.
What is the revenue of Daiichi Sankyo Company Limited (DSKYF)?
Daiichi Sankyo Company Limited reported trailing-twelve-month revenue of about ¥2.1T (latest available figure, as of Sep 28, 2026).
Does Daiichi Sankyo Company Limited pay a dividend?
Daiichi Sankyo Company Limited currently shows a dividend yield of about 4.24% relative to its recent price (as of Sep 28, 2026).
What is the intrinsic value of Daiichi Sankyo Company Limited (DSKYF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daiichi Sankyo Company Limited it is $8.25 per share (as of Sep 28, 2026), against a price of $17.60. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Daiichi Sankyo Company Limited stock overvalued or undervalued in 2026?
As of Sep 28, 2026, DSKYF trades above its calculated fair value: price $17.60, fair value $8.25, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DSKYF?
No. The price is what the market pays today ($17.60); the fair value is what the company's own numbers justify ($8.25). For Daiichi Sankyo Company Limited the two are $9.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Daiichi Sankyo Company Limited worth?
The market values Daiichi Sankyo Company Limited at about $32.6B (market capitalisation, as of Sep 28, 2026). Per share that is $17.60; our models calculate a fair value of $8.25 per share.
What do the bullish and bearish scenarios say about DSKYF?
Our models span a range for Daiichi Sankyo Company Limited: cautious scenario $5.93, base $8.25, optimistic $10.91 per share (as of Sep 28, 2026, price $17.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DSKYF?
Daiichi Sankyo Company Limited trades at a price-to-earnings ratio of 20.0 (as of Sep 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.25 is built from several models across several years. Other multiples: PEG 1.7, P/B 3.1, P/S 2.4, EV/EBITDA 15.6.
What is the PEG ratio of DSKYF?
The PEG ratio of Daiichi Sankyo Company Limited is 1.75 (P/E divided by earnings growth, as of Sep 28, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Daiichi Sankyo Company Limited (DSKYF)?
Balance-sheet figures for Daiichi Sankyo Company Limited (as of Sep 28, 2026): return on equity 15.8%, debt of 0.06 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is DSKYF from its 52-week high?
Daiichi Sankyo Company Limited trades at $17.60, about 37% below its 52-week high of $28.09 and 19% above the low of $14.76 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $8.25 is for.
Which stocks are comparable to Daiichi Sankyo Company Limited?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daiichi Sankyo Company Limited stock attractive at the current price?
The data as of Sep 28, 2026: price $17.60, calculated fair value $8.25 (−53%), Quality Score 51/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DSKYF calculated?
We run Daiichi Sankyo Company Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Daiichi Sankyo Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daiichi Sankyo Company Limited (DSKYF)?
The closing price on Oct 2, 2026 was $17.60. Our model-based fair value is $8.25, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daiichi Sankyo Company Limited right now?
The price sits above even our optimistic bull case ($10.91). The favourable scenario is already priced in. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($5.93 to $10.91) leaves room in how you read the outcome.
Where does the earnings growth of Daiichi Sankyo Company Limited (DSKYF) come from?
Earnings per share at Daiichi Sankyo Company Limited grew +6.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +8.9 %, EBIT margin +0.8 %, tax rate +1.2 %, residual (interest, one-offs) −3.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Daiichi Sankyo Company Limited

How large is the market capitalisation of Daiichi Sankyo Company Limited (DSKYF)?
The market capitalisation of Daiichi Sankyo Company Limited is $32.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daiichi Sankyo Company Limited (DSKYF)?
The price-to-sales ratio of Daiichi Sankyo Company Limited is 2.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daiichi Sankyo Company Limited (DSKYF)?
Earnings per share at Daiichi Sankyo Company Limited are $0.8800 (price ÷ EPS = P/E 20.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daiichi Sankyo Company Limited (DSKYF)?
The dividend yield of Daiichi Sankyo Company Limited is 4.2% (payout 84.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daiichi Sankyo Company Limited (DSKYF)?
The net margin of Daiichi Sankyo Company Limited is 12.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daiichi Sankyo Company Limited (DSKYF)?
The return on equity (ROE) of Daiichi Sankyo Company Limited is 15.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daiichi Sankyo Company Limited (DSKYF)?
On an EBIT basis the return on assets of Daiichi Sankyo Company Limited is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daiichi Sankyo Company Limited (DSKYF)?
The operating margin of Daiichi Sankyo Company Limited is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daiichi Sankyo Company Limited (DSKYF)?
Revenue at Daiichi Sankyo Company Limited is growing +13.7% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daiichi Sankyo Company Limited (DSKYF)?
Earnings per share at Daiichi Sankyo Company Limited are growing −50.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daiichi Sankyo Company Limited (DSKYF) generate?
The free cash flow of Daiichi Sankyo Company Limited is −¥51.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Daiichi Sankyo Company Limited (DSKYF) hold?
Daiichi Sankyo Company Limited holds more cash than debt, ¥150B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Daiichi Sankyo Company Limited in the live analysis

One click puts Daiichi Sankyo Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.